Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05636579 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Assess Safety and Tolerability of Multiple Doses of EO2002

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 8, 2025 (before its estimated December 9, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jul 30, 2025 to Dec 9, 2025
    • Study completion date: Dec 2025 to Dec 9, 2025
    v3
  2. Primary completion date: Sep 30, 2023 to Jul 30, 2025
    • Study completion date: Mar 2024 to Dec 2025
    • Start date changed from estimate of Dec 1, 2022 to Nov 8, 2022
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical study is to assess the safety of multiple intracameral injections of EO2002 with and without topical Ripasudil.
Trial Details
NCT Number NCT05636579
Lead Sponsor Asociación para Evitar la Ceguera en México
Collaborators: Emmecell
Conditions
(from sponsor)		 Corneal Edema, Corneal Endothelial Dystrophy, Endothelial Dysfunction, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy, Bullous Keratopathy, Pseudophakic Bullous Keratopathy, Corneal Edema Pseudophakic
Related terms Corneal Dystrophy, Posterior Polymorphous, 1, Corneal Edema, Fuchs' Endothelial Dystrophy
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov